Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price objective of $12.00 for the company and are forecasting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also given Brainstorm Cell Therapeutics an industry rank of 98 out of 265 based on the ratings given to related companies.

Separately, Maxim Group set a $9.00 price target on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 16th.

Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded up $0.02 during mid-day trading on Friday, reaching $4.00. 112,185 shares of the company’s stock were exchanged, compared to its average volume of 134,203. Brainstorm Cell Therapeutics has a one year low of $2.07 and a one year high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter last year, the firm earned ($0.09) EPS. equities analysts predict that Brainstorm Cell Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. KCG Holdings Inc. increased its position in shares of Brainstorm Cell Therapeutics by 4.6% during the first quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 1,820 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Brainstorm Cell Therapeutics by 2.8% in the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after purchasing an additional 17,657 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in shares of Brainstorm Cell Therapeutics in the second quarter valued at approximately $2,759,000. Institutional investors and hedge funds own 13.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Brainstorm Cell Therapeutics Inc. (BCLI) Receives Average Rating of “Strong Buy” from Brokerages” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/04/brainstorm-cell-therapeutics-inc-bcli-receives-average-rating-of-strong-buy-from-brokerages.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.